#coinfection

A clinic in Baltimore showed great success in eradicating hep C among a traditionally challenging population.

Millions of Americans have chronic hepatitis virus—a leading cause of liver cancer—and don’t even know it.

A major academic center found only two cases of on-the-job infections via cuts in a 13-year period.

Researchers analyzed data from a cohort to understand what factors help predict whether someone with HCV will later contract HIV.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

The risk appears higher among those more recently infected with HIV and those with a higher HIV viral load.

Real-world data showed Merck’s hep C regimen performed well among a population with genotypes 1 or 4 and multiple other health conditions.

Both those with and without compensated cirrhosis saw high hep C cure rates in a recent trial.

The prevalence of each virus is up to three times higher among homeless versus non-homeless veterans.

This elevated risk, seen among a group largely uncured of hep C, remained even when factoring out liver cancer.

A meta-analysis of major clinical trials of hepatitis C treatments identified various subgroups who have unmet needs.

The major players in the hep C pharmaceutical market are still reaching for improved treatments, with two key approvals expected this year.

HIV/HCV-positive women and indigenous people are much less likely to receive treatment for hep C.

About 3 percent of nearly 3,000 cirrhotic HIV/HCV-positive men in major registries developed liver cancer in a recent analysis.

But not as well as those with compensated cirrhosis or no cirrhosis.

However, in a recent study those who had been treated for hep C before did not fare as well.